234 related articles for article (PubMed ID: 11991676)
1. Clinical cancer research 2001: new agents and therapies.
Verweij J; de Vries EG
Drug Resist Updat; 2001 Aug; 4(4):217-23. PubMed ID: 11991676
[No Abstract] [Full Text] [Related]
2. Bundling next-generation cancer therapies for synergy.
Kling J
Nat Biotechnol; 2006 Aug; 24(8):871-2. PubMed ID: 16900109
[No Abstract] [Full Text] [Related]
3. Are targeted therapies really targeted?
Schilsky RL
Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
[No Abstract] [Full Text] [Related]
4. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
Arteaga CL; Baselga J
Clin Cancer Res; 2003 May; 9(5):1579-89. PubMed ID: 12738709
[No Abstract] [Full Text] [Related]
5. Developing targeted therapies for lung cancer.
Gandara DR
Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
[No Abstract] [Full Text] [Related]
6. Localized delivery of anti-cancer drugs by electroporation.
Featherstone C
Mol Med Today; 1998 Feb; 4(2):47. PubMed ID: 9547785
[No Abstract] [Full Text] [Related]
7. Multidrug resistance in cancer therapy: role of the microenvironment.
Galmarini CM; Galmarini FC
Curr Opin Investig Drugs; 2003 Dec; 4(12):1416-21. PubMed ID: 14763126
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies: aiming for the bull's-eye.
Gaguski ME
ONS Connect; 2007 Jul; 22(7):8-12. PubMed ID: 17694778
[No Abstract] [Full Text] [Related]
9. Emerging targeted treatments for malignant glioma.
Mulholland PJ; Thirlwell C; Brock CS; Newlands ES
Expert Opin Emerg Drugs; 2005 Nov; 10(4):845-54. PubMed ID: 16262566
[TBL] [Abstract][Full Text] [Related]
10. Facilitating patient-centered cancer research and a new era of drug discovery.
Niederhuber JE
Oncologist; 2009 Apr; 14(4):311-2. PubMed ID: 19365096
[No Abstract] [Full Text] [Related]
11. New targets for cancer chemotherapy.
Murgo AJ; Dancey J; Eckhardt SG; Hidalgo M; Arbuck SG; Zerivitz K; Blaylock BA
Cancer Chemother Biol Response Modif; 2002; 20():239-72. PubMed ID: 12703208
[No Abstract] [Full Text] [Related]
12. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
[No Abstract] [Full Text] [Related]
13. Molecular perspectives on the non-responder phenomenon.
Jackson DB
Drug Discov Today; 2009 Apr; 14(7-8):373-9. PubMed ID: 19200455
[TBL] [Abstract][Full Text] [Related]
14. [The pathologist and targeted therapies in oncology].
Bertheau P
Ann Pathol; 2009 Nov; 29 Spec No 1():S69-70. PubMed ID: 19887258
[No Abstract] [Full Text] [Related]
15. Targeted therapies: the answer to individualized treatment?
Hutchinson L
Nat Clin Pract Oncol; 2007 Jun; 4(6):323. PubMed ID: 17534387
[No Abstract] [Full Text] [Related]
16. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
Perry WL; Weitzman A
Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
[TBL] [Abstract][Full Text] [Related]
17. Integrins and extracellular matrix: a novel mechanism of multidrug resistance.
Elliott T; Sethi T
Expert Rev Anticancer Ther; 2002 Aug; 2(4):449-59. PubMed ID: 12647988
[TBL] [Abstract][Full Text] [Related]
18. Physical mechanisms and methods employed in drug delivery to tumors.
Besić E
Acta Pharm; 2007 Sep; 57(3):249-68. PubMed ID: 17878107
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles for drug delivery in cancer treatment.
Haley B; Frenkel E
Urol Oncol; 2008; 26(1):57-64. PubMed ID: 18190833
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates for cancer: poised to deliver?
Hughes B
Nat Rev Drug Discov; 2010 Sep; 9(9):665-7. PubMed ID: 20811367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
